{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:39:04Z","timestamp":1770485944522,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.ophtha.2013.01.031","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T12:49:25Z","timestamp":1366202965000},"page":"1201-1209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Analysis of a Novel Protocol of Pulsed Intravenous Cyclophosphamide for Recalcitrant or Severe Ocular Inflammatory Disease"],"prefix":"10.1016","volume":"120","author":[{"given":"Ana M.","family":"Suelves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl A.","family":"Arcinue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Mar\u00eda","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan N.","family":"Kruh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2013.01.031_bib1","series-title":"Diagnosis and Treatment of Uveitis","author":"Foster","year":"2002"},{"key":"10.1016\/j.ophtha.2013.01.031_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.01.031_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in Northern California: the Northern California Epidemiology of Uveitis Study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.01.031_bib4","series-title":"Diagnosis and Treatment of Uveitis","author":"Foster","year":"2002"},{"key":"10.1016\/j.ophtha.2013.01.031_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1076\/ocii.10.4.263.15592","article-title":"Uveitis: a global perspective","volume":"10","author":"Chang","year":"2002","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2013.01.031_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.01.031_bib7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0190-9622(84)80193-0","article-title":"Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses","volume":"11","author":"Ahmed","year":"1984","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ophtha.2013.01.031_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<542::AID-CNCR23>3.0.CO;2-Y","article-title":"The history of the oxazaphosphorine cytostatics","volume":"78","author":"Brock","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ophtha.2013.01.031_bib9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de L\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ophtha.2013.01.031_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2013.01.031_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0002-9343(84)90654-5","article-title":"Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis","volume":"76","author":"Scott","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.ophtha.2013.01.031_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in\u00a0patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2013.01.031_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/ard.2002.003574","article-title":"EULAR randomized controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisone followed by azathioprine and prednisolone in lupus nephritis","volume":"63","author":"Yee","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.01.031_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bjo.81.2.130","article-title":"Successful treatment of optic neuropathy in association with systemic lupus erythematous using intravenous cyclophosphamide","volume":"81","author":"Rosenbaum","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2013.01.031_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/ard.56.8.481","article-title":"Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide","volume":"56","author":"Martin-Suarez","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.01.031_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2133.2009.09590.x","article-title":"Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus","volume":"162","author":"Saha","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ophtha.2013.01.031_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0733-8635(05)70194-7","article-title":"Pulse intravenous cyclophosphamide therapy for dermatologic disorders","volume":"18","author":"Fox","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ophtha.2013.01.031_bib18","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.01.031_bib19","first-page":"265","article-title":"Case of uveitis of unknown etiology treated with nitrogen mustards","volume":"41","author":"Roda Perez","year":"1951","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.ophtha.2013.01.031_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.01.031_bib21","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ophtha.2003.08.034","article-title":"Pulsed IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety","volume":"111","author":"Durrani","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2013.01.031_bib22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00005792-197311000-00002","article-title":"Wegener's granulomatosis: studies in eighteen patients and a review of the literature","volume":"52","author":"Fauci","year":"1973","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ophtha.2013.01.031_bib23","first-page":"123","article-title":"Treatment of severe refractory uveitis with intravenous cyclophosphamide","volume":"21","author":"Rosenbaum","year":"1994","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2013.01.031_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.01.031_bib25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/ard.2005.046193","article-title":"Long-term remission of Sj\u00f6gren's syndrome associated aggressive B cell non-Hodgkin\u2019s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)","volume":"65","author":"Voulgarelis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2013.01.031_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1167\/iovs.05-0789","article-title":"Inter- and intramolecular epitope spreading in equine recurrent uveitis","volume":"47","author":"Deeg","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2013.01.031_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ophtha.2013.01.031_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2005.03.005","article-title":"Role of intramolecular epitope spreading in pemphigus vulgaris","volume":"116","author":"Salato","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ophtha.2013.01.031_bib29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.1780380815","article-title":"Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study","volume":"38","author":"Radis","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2013.01.031_bib30","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2013.01.031_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study","volume":"15","author":"Kempen","year":"2008","journal-title":"Ophthalmic Epidemiol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642013000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642013000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:04:08Z","timestamp":1758981848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642013000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0161642013000468"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.031","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of a Novel Protocol of Pulsed Intravenous Cyclophosphamide for Recalcitrant or Severe Ocular Inflammatory Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}